Melior Enters Research Collaboration with AstraZeneca

EXTON, Pa.--()--Melior Discovery, Inc. announced today that it has signed an agreement with AstraZeneca PLC under which Meliors in-vivo theraTRACE® indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds.

Our agreement represents a significant opportunity for Melior to deliver value to AstraZeneca through the application of our unique and innovative in vivo testing platform, said Andrew Reaume, PhD, President and CEO of Melior. We look forward to a productive collaboration.

Melior Discovery Overview

Melior Discovery is leading the transformation of drug repositioning with its unique theraTRACE platform of multiplexed in vivo models. Melior is using theraTRACE to both build an internal pipeline of development candidates as well as sharing this capability with pharmaceutical and biotechnology company partners. In the former case, Melior identifies and develops privileged compounds that have been discontinued by other companies for lack of efficacy in their original indications. Melior is also able to identify appropriate compounds for repositioning by leveraging a close working relationship with the renowned medicinal chemist, Dr. Christopher Lipinski. In its partnered arrangements, Melior offers pharmaceutical partners an approach to expand their late-stage pipelines with safe, high-quality drug candidates

Melior Discovery is located in Exton, PA.

Contacts

Melior Discovery, Inc.
Andrew Reaume, PhD
President & CEO
1-610-280-0633
areaume@meliordiscovery.com

Contacts

Melior Discovery, Inc.
Andrew Reaume, PhD
President & CEO
1-610-280-0633
areaume@meliordiscovery.com